Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Half-year Report

March 2, 2021
RNS Number : 8349Q Renalytix AI PLC 02 March 2021     Renalytix AI plc ("RenalytixAI", the "Company" or the "Group")   Half-year Report   Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on

University of Utah Kidney Health Partnership

February 24, 2021
RNS Number : 1616Q Renalytix AI PLC 24 February 2021   This announcement contains inside information   Renalytix AI plc (" RenalytixAI " or the " Company ")   The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health   Innovative partnership to enable health system-wide

Notice of Results

February 23, 2021
RNS Number : 9649P Renalytix AI PLC 23 February 2021     Renalytix AI plc (" RenalytixAI " or the " Company ")   RenalytixAI to announce Financial Results for six and three months ended December 31, 2020   NEW YORK , February 23, 2021   - Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX), the

ASN & Renalytix to Co-Host Capital Markets Day

February 4, 2021
RNS Number : 9849N Renalytix AI PLC 04 February 2021     Renalytix AI plc (" RenalytixAI " or the " Company ")   American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health     Event Featuring Leading Clinicians, Biotech Innovators and Federal Health

Price Monitoring Extension

January 13, 2021
RNS Number : 6057L Renalytix AI PLC 13 January 2021   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

Finalization of MCIT rule for coverage pathway

January 13, 2021
RNS Number : 4713L Renalytix AI PLC 13 January 2021   This announcement contains inside information   Renalytix AI plc (" RenalytixAI " or the " Company ")   Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics  
Displaying 11 - 20 of 169